Suven Life Sciences Statistics
Total Valuation
Suven Life Sciences has a market cap or net worth of INR 33.35 billion. The enterprise value is 30.96 billion.
Market Cap | 33.35B |
Enterprise Value | 30.96B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
Earnings Date | Oct 25, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Suven Life Sciences has 218.07 million shares outstanding. The number of shares has increased by 10.71% in one year.
Shares Outstanding | 218.07M |
Shares Change (YoY) | +10.71% |
Shares Change (QoQ) | -0.08% |
Owned by Insiders (%) | 2.27% |
Owned by Institutions (%) | 13.85% |
Float | 58.94M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 374.00 |
PB Ratio | 12.35 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -28.40 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 0.26 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,048.65 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | -26.37% |
Revenue Per Employee | 631,319 |
Profits Per Employee | -7.73M |
Employee Count | 141 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.13% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +119.13% |
50-Day Moving Average | 137.74 |
200-Day Moving Average | 109.85 |
Relative Strength Index (RSI) | 60.45 |
Average Volume (20 Days) | 64,522 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Suven Life Sciences had revenue of INR 89.02 million and -1.09 billion in losses. Loss per share was -5.01.
Revenue | 89.02M |
Gross Profit | 80.77M |
Operating Income | -1.37B |
Pretax Income | -1.10B |
Net Income | -1.09B |
EBITDA | -1.31B |
EBIT | -1.37B |
Loss Per Share | -5.01 |
Balance Sheet
The company has 2.40 billion in cash and 7.10 million in debt, giving a net cash position of 2.39 billion or 10.97 per share.
Cash & Cash Equivalents | 2.40B |
Total Debt | 7.10M |
Net Cash | 2.39B |
Net Cash Per Share | 10.97 |
Equity (Book Value) | 2.70B |
Book Value Per Share | 12.38 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 90.74% |
Operating Margin | -1,534.99% |
Pretax Margin | -1,236.05% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Suven Life Sciences does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.71% |
Shareholder Yield | -10.71% |
Earnings Yield | -3.28% |
FCF Yield | n/a |
Stock Splits
The last stock split was on March 23, 2007. It was a forward split with a ratio of 4.
Last Split Date | Mar 23, 2007 |
Split Type | Forward |
Split Ratio | 4 |